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ABSTRACT
Background: Ten percent of gastric cancer (GC) cases are
familial, with one third resulting from a mutation in the
tumor suppressor gene CDH1. Loss of this important struc-
ture can result in hereditary diffuse gastric cancer (HDGC),
which carries a high mortality if early diagnosis is not made.
Despite its clear genetic origin, optimal management of
HDGC family members is controversial, as the utility and
efficacy of current cancer screening programs for mutation
carriers are unproven.
Methods: A 53-year-old Caucasian woman was initially seen
for genetic screening because multiple family members had
mutations of the CDH1 gene. Her pedigree analysis demon-
strated 4 generations of gastric cancer, and 2 of the genera-
tions carried the CDH1 germline mutation, consistent with
HDGC. At endoscopy, the patient’s gastric mucosa was nor-
mal and random biopsies were also normal. The patient
underwent a laparoscopic total gastrectomy.
Results: The gross examination of her stomach appeared
normal. On histologic examination, however, the stomach
was found to have diffuse (signet ring cell) adenocarci-
noma in-situ with 11 microscopic foci of invasive adeno-
carcinoma limited to the lamina propria.
Conclusion: Our case is the first reported prophylactic
total gastrectomy utilizing a laparoscopic approach, and it
highlights the importance of taking a thorough family
history and obtaining a pedigree analysis. Endoscopic
screening in HDGC cannot rule out diffuse GC, because
the stomach and biopsies can be normal despite the pres-
ence of adenocarcinoma. Therefore, our case supports the
recommendation for prophylactic gastrectomy in HDGC.
Key Words: Laparoscopic-assisted total gastrectomy,
Gastric cancer.
INTRODUCTION
Gastric cancer (GC) will account for approximately 22,000
cases of cancer in the United States in 2006, with 10% being
familial.1 Of the familial gastric cancers, approximately one
third result from a mutation in the tumor suppressor gene
CDH1, which normally encodes for the protein E-cadherin.2
This mutation has an autosomal dominant inheritance with a
high rate of penetrance. Patients who are CDH1 positive are
at high risk for diffuse gastric cancer, which carries a poor
prognosis if an early diagnosis is not made.
The CDH1 gene is located on chromosome16p22.1 and
contains 2.6kb of coding sequences with 16 exons. It en-
codes for a transmembrane protein, E-cadherin, with 5 tan-
demly repeated extracellular domains and a cytoplasmic
domain that connects to an actin cytoskeleton through a
complex with , , and  catenins.3 The mature protein
product belongs to the family of cell-cell adhesion mole-
cules. E-cadherin is important for establishing cell polarity
and maintaining normal tissue morphology and cellular dif-
ferentiation.3 Loss of the CDH1 gene function impairs cell
adhesiveness as well as cell proliferation pathways.4 The
mechanism by which these E-cadherin mutations actually
lead to cancer is complex and not well understood. The
disrupted cell adhesion is likely to play a role in the
initiation of cell proliferation by allowing escape from
growth control signals. Alternatively, the cytoplasmic do-
main of E-Cadherin may modulate specific signaling path-
ways by inhibiting the availability of free cytoplasmic
-catenin, in a manner complementary to the product of
the colorectal tumor-suppressor gene APC.5 Germline
CDH1 mutations have an approximately 70% to 80% pen-
etrance.6 Each individual in a cancer syndrome family has
a 50% chance of inheriting the mutant gene, due to the
autosomal dominant transmission.4 Gene carriers have a
cumulative lifetime risk estimated at 67% for men and 83%
for women7 of developing GC by the age of 80.
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CASE REPORTHDGC is defined as1 families with 2 or more documented
cases of pathologically proven diffuse GCs in first- or
second-degree relatives with at least one diagnosed be-
fore the age of 50, or2 3 or more cases of documented
diffuse gastric cancer in first- or second-degree relatives,
independent of age of onset.8 It is predicted that up to
25% of families that fit these criteria will have inactivating
germline CDH1 mutations. Early onset of phenotypic ex-
pression is a defining feature of inherited malignancies, as
evidenced by the vast majority of families with truncating
CDH1 mutations that fulfill the above diagnostic criteria.
Despite its clear genetic origin, optimal management of
HDGC family members has been controversial. Early ge-
netic screening and testing is mandatory, with prompt
intervention for affected individuals. There are currently
no methods available to predict which mutation carrier
will develop phenotypic expression (ie, diffuse gastric
cancer). The utility and efficacy of current surveillance
programs for CDH1 mutation carriers are unproven,9
which has given credence to the recommendation for
prophylactic gastrectomy.8
Endoscopic screening and surveillance is inappropriate in
the great majority of cases of CDH1 germ-line mutations,
as patients usually have normal-appearing gastric mucosa
endoscopically. Random biopsies are often negative when
in fact the histologic specimen often has multiple foci of
carcinoma in situ and invasive carcinoma with negative
biopsies. Therefore, prophylactic total gastrectomy is war-
ranted in this high-risk group.
CASE REPORT
A 53-year-old asymptomatic Caucasian female was re-
ferred for prophylactic total gastrectomy because she was
found to carry a mutation of the tumor suppressor gene
CDH1. Multiple family members had died from gastric
cancer. Her grandmother died from diffuse gastric cancer
at age 63, and of her grandmother’s 8 children, 7 died from
diffuse gastric cancer at ages ranging from 26 years to 67
years of age. Among her (third) generation, 13 cousins
including herself ultimately underwent prophylactic total
gastrectomy after testing positive for the CDH1 mutation.
Pedigree analysis of her family shows that the family has
an inheritable gastric cancer that exhibits autosomal dom-
inant transmission with high penetrance (Figure 1).
The patient denied any gastrointestinal symptoms. She
had no significant past medical history. Surgical history
was significant for a tubal ligation. She did not take any
medications. Her physical examination was unremark-
able. Previous upper endoscopy revealed no abnormali-
ties and random gastric biopsies were unremarkable.
After extensive genetic counseling and discussions regard-
ing the risks and benefits, she elected to undergo a pro-
phylactic total gastrectomy. Laparoscopic hand-assisted
total gastrectomy was performed with Roux-en-Y recon-
struction. The patient was placed in the lithotomy position
with the operating surgeon positioned between the legs.
A total of 4 ports were used (three 5-mm ports and one
12-mm port) in addition to the hand port (Figure 2). The
jejunojejunostomy (JJ) was created with a linear laparo-
scopic stapling device, and the common channel enteros-
tomy was closed with a running full-thickness suture. The
mesenteric defect at the JJ was closed. The Roux limb was
brought in a retrocolic fashion, and the mesocolic defect
including Peterson’s defect was closed. The Roux limb
was 60cm in length. With the patient in full reverse Tren-
delenberg, gastric resection was performed and the spec-
imen removed through the hand port. Gross examination
of the resected stomach was performed. Esophagojejunos-
tomy was performed using a #21 EEA stapler. The anvil
was passed transorally. Esophageal and duodenal mucosa
were confirmed in the specimen before closure.
The resected stomach was grossly unremarkable. Only
microscopic examination of the entire gastric mucosa re-
vealed widespread adenocarcinoma in situ (Figure 3)
and 11 foci of invasive adenocarcinoma limited to the
lamina propria (Figures 4). An additional finding was of
hypervacuolation of the foveolar epithelium (globoid
changes), and slight chronic active gastritis. The histolog-
ical features of the tumor, including its signet ring cell
morphology, its multifocality, and its superficial distribu-
tion, and the associated globoid changes of normal fove-
olar mucosa have been described in prophylactic gastrec-
tomy of patients with E-cadherin germ-line mutations.10,11
The patient’s postoperative course was uneventful. She
had return of bowel function on postoperative day 3 and
was allowed to eat. She was discharged home on postop-
erative day 4 tolerating a postgastrectomy diet. She devel-
oped a stricture at the esophagojejunal anastomosis 6
weeks postoperatively, which was successfully treated
with endoscopic balloon dilation. More than one year
after the surgery, she is disease free and doing well.
DISCUSSION
Sokoloff is credited for the earliest recognition of a gastric
cancer prone family (the Bonaparte family).12 Napoleon
Bonaparte died in 1821 while in his sixth year in exile on
JSLS (2007)11:142–147 143St. Helena. His postmortem examination revealed a per-
forated malignant gastric ulcer.13 At 52, on his death bed,
he was heard to utter “pylorus. . . my father’s pylorus.”12
His father died from an autopsy proven gastric cancer, and
it has been proposed that his grandfather, his brother, and
3 sisters also died from GC.12 Familial gastric cancer in a
kindred of New Zealand Maori ethnicity was originally
reported in 1964, and the pedigree pattern was consistent
with an autosomal dominant inheritance.14 It was not until
1998 that germline truncating mutations of the CHD1
tumor suppressor gene were described in 3 New Zealand
Maori families predisposed to diffuse GC.6 This led to the
formation of the International Gastric Cancer Linkage
Consortium (IGCLC) where the name “hereditary diffuse
gastric cancer” (HDGC) was designated.8
There have been several reports of prophylactic gastrectomy
for CDH1 gene mutation carriers in the literature (Table 1).
Lewis et al15 reported on 6 patients from 2 families, and all
patients recovered uneventfully and were discharged on
average 7 days postoperatively. Chun et al16 reported on 5
patients from a single family with no reported complications.
Newman and Mulholland17 reported on 2 patients from the
same family. All patients underwent open total gastrectomy
with Roux-en-Y reconstruction. Two other groups18,19 re-
ported a total of 12 patients, but the details of their periop-
erative care was not reported.
Based on this review, our case brings the total number of
prophylactic gastrectomies to 26, and, to the best of our
knowledge, our case is the first prophylactic laparoscopic-
Figure 1. Genealogy demonstrating 4 generations of stomach cancer, 2 of which carried the CDH1 germline mutation, consistent with
hereditary diffuse gastric cancer (HDGC). Thirteen patients had prophylactic gastrectomy, including the proband who underwent
successful total laparoscopic gastrectomy. Eighteen patients were identified as having gastric cancer, and 11 of those were identified
as carrying the CDH1 tumor suppressor gene mutation. Three patients were identified as carrying the CDH1 tumor suppressor gene
mutation but did not have cancer.
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efits of laparoscopic total gastrectomy are clearly demon-
strated in our case. The patient had early return of bowel
function, tolerated oral intake early, and was discharged
on postoperative day 4. This is in contrast to open gas-
trectomies where the average length of stay ranges from 7
days to 11 days.
Figure 2. Diagram of patient in lithotomy position with location of surgeon, assistants, and placement of laparoscopic ports.
Figure 3. Adenocarcinoma in situ, showing neoplastic goblet
cells within foveolar epithelium (as outlined by black arrows).
Figure 4. Focus of invasive adenocarcinoma, showing signet
ring cells in the lamina propria distorting gastric glands (as
outlined by black arrows).
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underwent prophylactic gastrectomy, including our pa-
tient, had foci of adenocarcinoma despite normal surveil-
lance endoscopy. This further establishes the role of pro-
phylactic gastrectomy in these patients; in fact, the surgery
that was intended to be prophylactic proved to be thera-
peutic and curative.
In regards to the laparoscopic versus the open technique,
definite conclusions cannot be made from one case, but
our preference for the laparoscopic approach is supported
by Usui et al20 who showed that time to first flatus, time to
initial oral intake, and postoperative hospital stay were
significantly shorter (P  0.05) in laparoscopic gastric
surgery than in open gastric surgery. Their report con-
cluded that laparoscopic-assisted total gastrectomy is suit-
able and feasible for early gastric cancer and has the
advantage of a shorter recovery time compared with that
for open total gastrectomy.
Laparoscopic total gastrectomy has been criticized be-
cause of the doubts that remain about its ability to satisfy
all the oncologic staging criteria met during conventional
open surgery. Although no long-term studies have been
conducted, adenocarcinoma in HDGC, when present, ex-
ists at a very early stage (TisN0M0). Therefore, the classi-
cal D1 or D2 dissection is not necessary. The guideline
given by the IGCLC is that when a total gastrectomy is
performed, it is essential to document the complete re-
moval of gastric mucosa by pathologically identifying rims
of esophageal and duodenal mucosa at the 2 ends of the
surgical specimen.8 Laparoscopic total gastrectomy with
Roux-en-Y reconstruction can satisfy this requirement
and, given the improved postoperative recovery and de-
creased morbidity, it is well suited for the asymptomatic,
cancer-susceptible patients found in HDGC families.
However, only surgeons experienced in advanced lapa-
roscopy should attempt laparoscopic gastrectomy.
Total gastrectomy is not without complications. Overall, the
30-day mortality for total gastrectomy ranges from 3% to
6%.21 However, considering that gastrectomy is usually per-
formed in older patients, the complication rate in a younger,
healthier population, such as those with HDGC undergoing
prophylactic gastrectomy, are expected to be much less, with
an estimated mortality of 1% to 2%.8 Long-term morbidity
after total gastrectomy is related to alteration of eating habits,
dumping syndrome, diarrhea, and weight loss. There is usu-
ally a 10% to 15% decrease in body weight, which is princi-
pally a decrease in body fat.21 Dumping syndrome occurs in
20% to 30% of patients but improves over time.22
Laparoscopic total gastrectomy for HDGC should not be
performed without genetic counseling and genetic testing.
The modified screening criteria as proposed by Suriano et
al19 should be used to determine which families should be
screened. The age at which genetic screening should be
initiated is controversial, because patients younger than
age 18 have undergone prophylactic gastrectomy.18 How-
ever, current consensus requires that the patient is able to
give informed consent.23
CONCLUSION
Genomics is playing an ever-greater role in clinical medicine.
This is highlighted in our case, in which a patient with a
CDH1 mutation within a family of HDGC underwent pro-
phylactic laparoscopic gastrectomy. Despite the normal ap-
pearance of the stomach endoscopically, many microscopic
foci of invasive adenocarcinoma were present. Thus, the
surgery was curative. This review highlights the poor prog-
nosis in those family members who did not receive gastrec-
Table 1.
Summary of All Previous Documented Open Prophylactic Gastrectomies
Series No. of
Patients
Reconstruction Mean Length
of Stay (d)
Foci of
Adenocarcinoma
(No. of Pts)
Complications
Lewis et al 6 Roux-en-Y 7 6 Stricture, SBO, septic
thrombophlebitis, dumping
Chun et al 5 Roux-en-Y 7 5 Nil
Charlton et al 6 Not reported Not reported 6 Not reported
Suriano et al 6 Not reported Not reported 5 Not reported
Newman 2 Roux-en-Y 11 0 Prolonged ileus, wound
infection, dumping
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sis. The penetrance in this family was high, with 70% of
family members who acquired the CDH1 gene mutation
developing diffuse gastric cancer.
Endoscopic screening in HDGC cannot be recommended
because the stomach will appear normal and biopsies can
and often fail to demonstrate the (signet ring cell) adeno-
carcinoma in situ or invasive adenocarcinoma that is in-
variably found in resected stomachs. Prophylactic gastrec-
tomy has provided many members of this family with
relief from gastric cancer with minimal complications. This
case further supports the current recommendation in the
literature for prophylactic gastrectomy in HDGC. Further-
more, we report that successful complete gastrectomy can
be accomplished laparoscopically without complication,
thus reducing the length of hospitalization and providing
a minimally invasive alternative to more traditional open
surgery. In fact, the laparoscopic approach should be
offered first to CDH1-positive patients.
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